These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35285220)

  • 1. Review of medication-assisted treatment for opioid use disorder.
    Ghanem N; Dromgoole D; Hussein A; Jermyn RT
    J Osteopath Med; 2022 Mar; 122(7):367-374. PubMed ID: 35285220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Treatments for Opioid Use Disorder.
    Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
    JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and co-managing medication treatment options for opioid use disorder.
    Kay A; Shmuts R; Beck M
    Intern Emerg Med; 2022 Oct; 17(7):2159-2165. PubMed ID: 35138549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
    Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
    J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-Assisted Treatment for Opioid-Use Disorder.
    Oesterle TS; Thusius NJ; Rummans TA; Gold MS
    Mayo Clin Proc; 2019 Oct; 94(10):2072-2086. PubMed ID: 31543255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
    Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
    J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
    Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
    J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 and treating incarcerated populations for opioid use disorder.
    Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
    J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
    Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
    J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
    Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
    Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
    Kennedy-Hendricks A; Barry CL; Stone E; Bachhuber MA; McGinty EE
    Drug Alcohol Depend; 2020 Nov; 216():108217. PubMed ID: 32810837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
    Fanucchi L; Springer SA; Korthuis PT
    Curr HIV/AIDS Rep; 2019 Feb; 16(1):1-6. PubMed ID: 30684117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.